Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642064 | 0.86 | NOS3 (0.54) | NOS3NOS1NOS2LMNAMAPT | |
| SCHEMBL12320090 | 0.82 | CYP2A6 (0.48) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL22468551 | 0.79 | GAA (0.41) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL28996531 | 0.79 | PDK2 (0.42) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL18748738 | 0.75 | ALDH1A1 (0.37) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL29535498 | 0.75 | HSP90AA1 (0.45) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL1083427 | 0.75 | HSP90AA1 (0.45) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL4436880 | 0.73 | KMT2A (0.49) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL30800073 | 0.73 | CNR2 (0.43) | NOS3NOS1NOS2LMNAALDH1A1 | |
| SCHEMBL4436882 | 0.72 | NOS3 (0.50) | NOS3NOS1NOS2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341793-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2007-01-17 | — | — | EP | disclosed |
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6927221-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1408040-B1 | Tricyclic fused heterocyclic compounds as CRFantagonists | EISAI CO LTD (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1238979-B1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6747034-B2 | CORTICOTROPIN-RELEASING FACTOR (CRF); SUCH AS 4-CHLORO-2-METHYL-5-NITRO-8-(2,4-DICHLORO)PHENYL-1,7-NAPHTHYRIDINE FOR TREATING STROKE, ANXIETY, DEPRESSION, AND/OR IRRITABLE BOWEL SYNDROME | NEUROCRINE BIOSCIENCES, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1341793-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC | 2002-10-17 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002040480-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266799-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | NOS3 1495/4885NOS1 1905/4885NOS2 2027/4885 |
| US-20020151557-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | NOS3 1495/4885NOS1 1905/4885NOS2 2027/4885 |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | NOS3 1632/4885NOS1 2421/4885NOS2 3046/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | NOS3 833/4885NOS1 1715/4885NOS2 1243/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | NOS3 833/4885NOS1 1715/4885NOS2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.